What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Mitochondrial constituents and metabolic products may give rise to immune activation; this is especially true for mitochondrial DNA, which can function as damage-associated molecular patterns (DAMPs) leading to inflammasome activation.
DAMPs and pathogen-associated molecular patterns (PAMPs) are primary drivers of inflammasome activity.
Dr. John Cush RheumNow
3 years 4 months ago
Treatment Options for Still's Disease
Gotta know if you're treating “systemic” or “articular” (arthritis) Still’s disease. Most Still’s patients have a dominance of one or the other. With certainty, the right therapy for the right symptoms can be chosen.
https://t.co/fPBk6PdCaD https://t.co/u3RfWsnyv6
Dr. John Cush RheumNow
3 years 4 months ago
Review of Clinical Trial measures in systemic sclerosis:
-RCTs focus on skin dz, ILD or Pulm HTN using mod. Rodnan skin (MRSS), 6-min walk
-FVC is surrogate measure for SSc-ILD
- Composites: CRISS, the EUSTAR-AI
-Future: Skin mRNA biomarkersTHBS1 and COMP https://t.co/2KD892VIUy https://t.co/9giddEl9I4
Still’s disease is a rare inflammatory disorder, affecting less than 1 person per 2000 people. This disease may occur in both children and adults, namely as systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).
The paediatric form was described by George Still in 1896, whereas the adult variant later by Eric Bywaters in 1971. However only the adult disease is identified by the name of Still.
Dr. John Cush RheumNow
3 years 4 months ago
11.5% of Crohns pts have TNFi use contraindications (either MS, CHF, neoplasia, infx risk, TNFi AE, comorbidities, SLE. Alternatively GI survey respondents use ustekinumab (76%), vedolizumab (249%), or tofacitinib (0.5%) https://t.co/6ApUz93iS0 https://t.co/PTmnsTd2Wh
ARD & RMD Open ARD_BMJ
3 years 4 months ago
Novel autoinflammatory disease with an ALPK1 gain-of-function mutation:
▶️ R etinal dystrophy
▶️ O ptic nerve oedema
▶️ S plenomegaly
▶️ A nhidrosis
▶️ H eadache
https://t.co/9GbjZLMFCo https://t.co/Bh0MkYmrDA
EnvisionRheumat ERheumat
3 years 4 months ago
🌏 Today is World Sjögren's Day!🌍
🩺 Sjögren's is not Just Dry eyes👁️ and Dry Mouth👅👄 - there's much more to it
There's still a lot about this 'invisible' #Autoimmune Disorder, we don't know
Clinical Features and Pathogenesis
#LetstalkaboutSjögrens
#MedTwitter
#RheumTwitter https://t.co/t9toed8MG7
Eric Topol EricTopol
3 years 4 months ago
Anyone who thinks BA.5 is just another variant isn't paying attention
>200,000 new cases yesterday. Vertical. https://t.co/x7wziHMZ9K
Peter Nash drpnash
3 years 4 months ago
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis https://t.co/6f9yZwUFPb Another IL17 looking promising in GCA!
Dr. John Cush RheumNow
3 years 4 months ago
213 #SLE pts were screened for Cryoglobulinemia (2013 -2017); CG is frequent in SLE (66%), but mostly asymptomatic. Mean levels 40mg/L (0-228). Cryo Vasculitis in 15% w/ purpura, ulcers, digit ischemia, arthritis, GN (5%) or CNS (19%) https://t.co/jRVXCj4MlV https://t.co/gamOOwkJ5R
Dr. John Cush RheumNow
3 years 4 months ago
Overdose deaths increased to 107 000 deaths in US in 2021, with significant racial disparity. Higher overdose rates seen in American Indian, Alaska Natives and Blacks. WORSE during COVID - 2020, overdose rates were 7 times higher in Blacks than Whites https://t.co/PMRo9gbzZl https://t.co/CgxgemyEA7
Dr. John Cush RheumNow
3 years 4 months ago
JAMA patient (resource) handout on Lumbar Spinal Stenosis! https://t.co/fl5K5Ve6fY https://t.co/aLHs6sKE1o
Dr. John Cush RheumNow
3 years 4 months ago
French study from 362 septic arthritis pts over 2 yrs., mean age was 64yrs, w/ high Charlson comorbidity index 3.5. Most common was Knee (39%), Staphylococcus (51%), Abx used 47d, surgery in 48%; 28% serious complications & 9.2% died https://t.co/PdddHsagFg https://t.co/3oHbW0tAjU
Dr. John Cush RheumNow
3 years 4 months ago
Spinal Findings on MRI May Not Signify SpA
Research indicates that rheumatologists should be cautious about diagnosing SpA on the basis of imaging alone.
https://t.co/Z4gox4cx9N https://t.co/PI9BCty8Bx
Dr. John Cush RheumNow
3 years 4 months ago
Leflunomide versus azathioprine in lupus nephritis? Study of 215 bx proven LN given either LEF or AZA - Renal flares were equal (15.7% v 17.8%), as was time to flare (16 mo vs AZA 14 mo); 24-hr proteinuria, creatinine, C3 and C4 improved similarly. https://t.co/2TWmweS2wy https://t.co/0YzlU4vfXP
Poster Hall